Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans by Lazzarato, Loretta et al.
 
 
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by 
agreement between Elsevier and the University of Turin. Changes resulting from the publishing process 
- such as editing, corrections, structural formatting, and other quality control mechanisms - may not be 
reflected in this version of the text. The definitive version of the text was subsequently published in 
[Bioorganic & Medicinal Chemistry 19 (2011) 5852–5860, DOI 10.1016/j.bmc.2011.08.018]. 
 
You may download, copy and otherwise use the AAM for non-commercial purposes provided that your 
license is limited by the following restrictions: 
 
(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND 
license.  
(2) The integrity of the work and identification of the author, copyright owner, and publisher must be 
preserved in any copy.  
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), [+ Digital Object Identifier link to the 
published journal article on Elsevier’s ScienceDirect® platform]  
Searching for New NO-Donor Aspirin-like Molecules: Furoxanylacyl 
Derivatives of Salicylic Acid and Related Furazans. 
 
Abstract 
A new group of derivatives of salicylic acid containing NO-donor furoxans, and the related des-
NO-furazans, were synthesized and evaluated as new aspirin-like molecules. Their stability was 
assessed in acid (pH 1) and physiological solutions (pH 7.4), and in human serum. No compound 
exhibited COX-inhibitory activity against COX-1 and COX-2 isoforms, when tested up to 100 lM, 
respectively, on isolated platelets and on monocytes. Phenylsulfonyl- and cyano-substituted 
furoxans inhibited platelet aggregation induced by collagen in human platelet-rich plasma, through 
a cGMP dependent mechanism. Furoxan derivatives displayed cGMP-dependent vasodilator 
activities, tested on rat aorta strips precontracted with phenylephrine. All products showed anti-
inflammatory activity similar to that of ASA, tested on rats by the carrageenan-induced paw edema 
assay. Unlike ASA, all products showed markedly reduced gastrotoxicity in a rat lesion model. 
 
Introduction 
The major limitation on the prolonged use of aspirin (ASA)
1
 (Fig. 1) is its gastrotoxicity, 
responsible for gastric ulceration, exacerbation of peptic ulcer symptoms, gastrointestinal 
hemorrhage, erosive gastritis, delay in ulcer healing and, in some cases, death.
1–3
 
This is a prominent problem, in view of the widespread use of ASA to treat headache, rheumatic 
pain and inflammation, as well as for its effective antithrombotic activity.
1,4,5
 A number of new 
therapeutic perspectives are emerging for this enigmatic and intriguing drug, including its ability to 
reduce the risk of colorectal adenoma or cancer, and that of the recurrence of colorectal adenoma in 
high risk patients.
6–8
 The beneficial pharmacological actions of ASA are predominantly dependent 
on its ability to inhibit both isoforms of the COX-enzyme, with a preference for the COX-1 isoform, 
with consequent inhibition of prostanoid production.
9
 Unlike the other nonsteroidal anti-
inflammatory drugs (NSAIDs), ASA irreversibly inhibits both COX-1 and COX-2, by forming a 
covalent bond with the serine residue (Ser530) positioned in the arachidonic acid-binding channel 
of the enzymes. COX-1 is prevalently a constitutive enzyme, present in many tissues and cells, 
including platelets, and it is thought to be largely responsible for the antithrombotic effect of ASA. 
By contrast, inhibition of the COX-2 enzyme, prevalently an inducible isoform expressed by 
inflammatory stimuli in many tissues, is largely responsible for the drug’s anti-inflammatory, 
analgesic, and antiproliferative actions.
9
 ASA’s gastrotoxicity involves local and systemic 
mechanisms.
1,10,11
 Local mechanisms include interaction with phospholipids, weakening of the 
hydrophobic surface barrier in membranes, and the diffusion and subsequent entrapment of the drug 
into the mucosal cell, with consequent trapping of hydrogen ions, or both. These events principally 
depend on the product’s pKa and lipophilicity. The systemic mechanisms are mainly related to the 
drug’s ability to inhibit the COX-1 enzyme present in gastric epithelial cells, and consequently to 
block the production of prostaglandins, known to be crucial in defending the gastric mucosa. In 
view of the gastrosparing and anti-inflammatory actions exerted by nitric oxide (NO),
12,13
 one of the 
strategies proposed to overcome the problem of ASA’s gastrotoxicity is that of linking the drug 
with an appropriate NO-donor moiety. Most such products are obtained by linking the NO-donor 
moieties to the carboxylic site of aspirin through an ester linkage (Fig. 1A).
14–17
 Recently, we 
proposed a new class of NO-donor aspirin-like molecules obtained by substituting the acetyl group 
of aspirin with acyl groups, containing nitrooxy NO-donor moieties (Fig. 1B).
18
 In order to explore 
the influence exerted by the nature of the NO-donor moiety on the pharmacological profile of this 
new type of products, we here describe the synthesis and pharmacological activity of a new class of 
compounds, obtained by substituting acyl groups containing NO-donor furoxan moieties for acetyl 
group of ASA (compounds 13, 14, 17 and 18, Fig. 2). Furoxans are NO-donors able to release NO 
through a mechanism different from that occurring for the organic esters of nitric acid. It is 
generally accepted that they can produce NO under the action of thiol cofactors,
19
 while nitrooxy 
derivatives require principally enzymatic metabolism.
20
 This new class of products might be 
expected to display a pharmacological profile different from that observed for the nitrooxy 
analogues,
21 
in the light of both the different structure and the different NO-release mechanism of 
the corresponding NO-donor moieties. In this study, the related furazan derivatives 13a, 14a, 17a 
and 18a (Fig. 2), devoid of NO-releasing (des-NO) properties, are also considered, for comparison 
purposes. 
Results and Discussion 
Chemistry 
The synthesis of the end products required the preliminary preparation of the carboxylic acid 4, 4a, 
5, 5a, 8, 8a, 10 and 10a (Scheme 1). Phenyl- and phenylsulfonyl-substituted compounds 4, 4a, 5 
and 5a, were obtained by oxidation of the corresponding alcohols 2, 2a, 3 and 3a with Jones reagent 
in acetone solution. To prepare carbamoyl- and cyano-substituted compounds 8, 8a, 10 and 10a, 
4-bromomethylfuroxan-3-carboxamide (6) was treated with methyl thioglycolate in acetonitrile 
solution in the presence of Et3N to give the ester 7. Ester 7, containing the furoxan ring, was 
reduced with trimethyl phosphite (P(OCH3)3) to give the resulting furazan ester 7a. Dehydration of 
7 and 7a with trifluoroacetic anhydride in THF, in the presence of pyridine (Py), afforded 9 and 9a. 
Hydrolysis of 7, 7a, 9 and 9a with 6 M hydrochloric acid in dioxane yielded the expected acids. The 
preparation of the final products 13, 13a, 14, 14a, 17, 17a, 18 and 18a is depicted in Scheme 2. The 
appropriate acids were transformed into the corresponding chlorides 11, 11a, 12, 12a, 15, 15a, 16 
and 16a. These products were immediately coupled with salicylic acid in THF or CH2Cl2 solution 
in the presence of pyridine to give the target compounds. 
Stability in aqueous buffered solutions and human serum 
The stability of all end products was studied in aqueous solutions at pH 1 and 7.4, as well as in 
human serum. The progress of the transformation was evaluated by high-performance liquid 
chromatography (HPLC). The results are shown in Table 1. All products remained largely 
unchanged after 3 h of incubation in acidic medium. At physiological pH, both furoxans and 
furazan analogues were transformed into salicylic acid, accompanied prevalently by the native 
heterocyclic acids. The transformation strictly followed first-order kinetics. The observed pseudo-
first-order rate constants (kobs) and the half-lives (t1/2, Table 1) were determined by fitting the 
remaining ester against time with one-phase exponential decay equation (Graph Pad, Prism 
software vers. 5). Analysis of Table 1 shows that the products containing a sulfur atom a-positioned 
to the ester function are less stable than the others, and that the stability of pairs of related furazan 
and furoxan esters is similar. Different results were obtained working in human serum, where the 
compounds can interact with serum esterases and other serum proteins, in particular with albumin. 
After 2 h, stoichiometric amounts of salicylic acid were recovered from carbamoyl- and cyano-
substituted compounds containing sulfur, 17, 17a, 18 and 18a. Conversely, the native acid 
components were only partly recovered because of their instability in this medium. In the case of 
the remaining products, the formation of salicylic acid was not stoichiometric, but was accompanied 
by a number of other metabolites. In all cases, the disappearance of the initial products followed a 
pseudo-first-order kinetics, with half-lives markedly lower than those measured at physiological 
pH, and falling within a narrower range. 
COX inhibitory activity 
Compounds were assayed for COX-1 and COX-2 inhibition. COX-1 inhibitory activity was 
evaluated on isolated humanplatelets. In this assay, washed platelets were treated with different 
concentrations of the products for 30 min, before stimulation of thromboxane B2 (TXB2) production 
with the calcium ionophore A23187. After a fixed time, the cells were lysed and the TXB2 produced 
was quantitated by EIA. COX-2 inhibitory activity was evaluated on isolated human monocytes, in 
which COX-2 protein expression had been induced by overnight lipopolysaccharide (LPS) 
treatment. After addition of arachidonic acid, PGE2 production was assessed by EIA. Neither the 
NO-donor furoxan derivatives nor the des-NO furazan analogues were able to inhibit either COX 
isoform, when tested up to 100 M. This is probably due to the steric bulk of the heterocyclic acyl 
moieties, which prevent binding of the products to the active cleft of the enzyme, and then its 
acylation. Conversely a number of nitrooxyacyl derivatives of salicylic acid, previously described 
by our group, were shown to be potent irreversible inhibitors of both enzymes.
21
 
Platelet anti-aggregatory activity 
Both the furoxan and the furazan series were studied for their action on collagen-induced platelet 
aggregation of human platelet- rich plasma. The results, expressed as IC50, or as percentage of 
inhibition at the highest concentration tested when IC50 could not be calculated, are reported in 
Table 2. The data show that the furazan derivatives display either no activity or very weak activity. 
The only exception is the amide compound 17a, which displays low antiaggregatory action. 
Compounds in the furoxan series display very weak antiaggregatory action, while the 
phenylsulfonyl- and the cyano-substituted members 14 and 18 behave as potent antiaggregatory 
agents. The potency of these two furoxan derivatives decreased if the tests were carried out in the 
presence of ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), a wellknown inhibitor of soluble 
guanylate cyclase (sGC), an enzyme that mediates the antiaggregatory effects of NO. This is thus in 
keeping with the involvement of NO in the antiaggregatory effects of furoxans. The NO-donor 
aspirin obtained by linking the 3-cyanofuroxan- 4-yl-methyl substructure present in 18 to the 
carboxylic group of the lead, through an ester bridge, possessed potent antiaggregatory activity. 
This activity was shown to be due to abundant NO-release in the platelets, following the synergistic 
effect of high intracellular concentrations of glutathione (GSH) and ascorbate in these kind of 
cells.
22
 The furoxan amide compound 17 acts as a rather good antiaggregatory agent; however, its 
antiplatelet activity was found not to be influenced by the presence of ODQ, suggesting that NO 
dependent sGC activation plays little or no role in this action. As in the case of the related 
furazancarboxyamide 17a, an antiaggregatory mechanism that is neither COX- nor NO-dependent 
must be involved. Indeed, preliminary results obtained with these two products indicate that they 
behave as antagonists at the thromboxane receptor (IC50 (CL 95%)0 M: 38 (37–38) and 39 (37–
42) for compound 17 and 17a, respectively). The above picture indicates that the potential value of 
this new series of furoxanylacyl derivatives of salicylic acid as anti-thrombotic agents is limited, 
since none of these compounds act as irreversible inhibitors of the COX-enzymes, unlike aspirin 
and some its nitrooxyacyl analogues.
21
 
Vasodilator activity 
The vasodilatory effects of the furoxan derivatives were evaluated on endothelium-denuded rat 
aorta strips, pre-contracted with phenylephrine. All the furoxan products were capable of relaxing 
the contracted tissue in a concentration-dependent manner. The vasodilator potencies, expressed as 
EC50, are shown in Table 2. Their order of potency was 14 > 18 > 13≥17. When the experiments 
were repeated in the presence of 1 M ODQ, the potencies decreased, in keeping with NO-induced 
activation of the sGC being the mechanism underlying this effect. The most potent products, 
namely 14 and 18, also displayed the most potent NO-dependent antiaggregatory activity. Two 
properties of this new class of vasodilators that differ from those of their nitrooxy analogues are of 
interest: their greater potency and the probable lack of tolerance development. This latter aspect was 
studied in vivo for the simple 4-hydroxymethylfuroxan-3-carboxyamide (CAS 1609),23 whose 
substructure is present in 17, and for the simple 4-ethoxy-3-phenylsulfonylfuroxan (CHF 2363),
24
 
whose substructure is present in 14. Both these two products were found to be devoid of tolerance 
development. 
Anti-inflammatory activity 
All products in the furoxan and furazan series were tested on carrageenan-induced paw edema in 
conscious rats, together with aspirin (ASA) and salicylic acid. Injection of carrageenan into the rat’s 
hind paw produced immediate swelling, which peaked at 4– 5 h. Aspirin, administered by the 
intragastric route at 120 mg/kg just prior to carrageenan injection, significantly reduced (43.0 ± 
3.3%) paw edema at 3 h, compared to vehicle-treated animals (Table 2). Salicylic acid acted 
similarly, reducing paw edema by 37%. The furoxan products significantly inhibited paw edema, 
from 37% to 55%, when administered intragastrically at doses equimolar with aspirin 120 mg/kg 
(Table 2). The most efficacious inhibitors were the phenylsulfonyl- and cyano-substituted furoxans 
14 and 18, for which inhibition reached 50% and 55%, respectively. Either the NO released by the 
products,
25
 and/or the salicylic acid deriving from their metabolic transformation, could be involved 
in this activity.
26
 The finding that the des-NO furazan analogues also displayed potent anti-
inflammatory action (about 40% inhibition) appears to minimize the role played by NO in the 
observed effects, suggesting conversely that salicylic acid plays a paramount role. Indeed, both 
salicylic acid and the present series of compounds are ineffective as inhibitors of prostanoid 
synthesis under in vitro conditions, while being as effective as aspirin in inhibiting the rat paw 
edema. As for the mechanism involved, it has been proposed that the inhibition of COX-2 enzyme 
induction (via inhibition of NFkB signaling) may represent the major mode of action of salicylates 
in vivo.
26
 Conversely, in some of the previously- described nitrooxy analogues, COX-acylation 
might also contribute to their in vivo anti-inflammatory activity. 
Acute gastric mucosal damage 
All compounds, including aspirin and salicylic acid as reference standards, were assessed for their 
ulcerogenic properties in conscious rats. The development of gastric lesions was assessed 3 h after 
intragastric administration of the compounds, and lesions were quantified by determining the 
‘lesion index’ on the basis of their greatest length in millimeters (Table 2). In the present study 
aspirin, administered at 120 mg/kg, produced macroscopically detectable gastric damage, 
characterized by mucosal necrosis and hemorrhage (lesion index = 50 ± 3.8). By contrast salicylic 
acid, tested under the same conditions, showed much lower gastrotoxicity, in keeping with findings 
that it lacks this side effect in experimental animals.
26
 All the NO-donor products, as well as their 
des-NO furazan analogues, also displayed greatly reduced gastrotoxicity when administered at 
doses equimolar with aspirin. In the light of the fact that the products are not COX-inhibitors, and 
of the finding that the des-NO furazan analogues are devoid of gastrotoxicity (Table 2), a possible 
explanation for this finding is that they behave in vivo essentially as pro-drugs of salicylic acid. By 
contrast, in the COX-inhibitor nitrooxyacyl analogues, a role of NO in the reduced gastrotoxicity 
must be considered. 
Conclusions 
A new series of salicylic acid derivatives, containing NO-donor furoxan moieties linked to the 
hydroxyl group through an ester bridge, were designed together with the corresponding des-NO 
furazan analogues. The furoxan derivatives display antiaggregatory, vasodilator and anti-
inflammatory properties, and show very limited gastrotoxicity when tested in conscious rats. The 
mechanisms responsible for these properties are somewhat different from those of the nitrooxy 
analogues previously described, due to both the different structure and the different NO-release 
mode of the respective NO-donor moieties. In particular in this new series of compounds, the 
antiaggregatory activity is dependent on the thiol-induced NO-release by furoxan moieties in 
platelets and the products are unable to inhibit COX-enzyme. The comparison with the 
corresponding des-NO furazans indicates that salicylic acid formed following hydrolysis under the 
action of serum esterases, is the main responsible of the anti-inflammatory activity of the series. 
The designed products are an emblematic example of how the appropriate selection of the NO-
releasing group is a critical aspect in designing NO-hybrid compounds. 
Experimental section 
Chemistry 
1
H and 
13
C NMR spectra were recorded on a Bruker Avance 300 at 300 and 75 MHz, respectively, 
using TMS as internal standard. Low resolution mass spectra were recorded with a Finnigan-Mat 
TSQ-700. Melting points were determined with a capillary apparatus (Büchi 540). Flash column 
chromatography was performed on silica gel (Merck Kieselgel 60, 230–400 mesh ASTM); PE 
stands for 40–60 petroleum ether. Progress of the reactions was monitored by thin layer 
chromatography (TLC) on 5 x 20 cm plates with a layer thickness of 0.25 mm. Anhydrous 
magnesium sulfate was used as drying agent for the organic phases. Organic solvents were removed 
under vacuum at 30 °C. Preparative HPLC was performed on a Lichrospher_ C18 column (250 x 25 
mm, 10 m) (Merck Darmstadt, Germany) with a Varian ProStar mod-210 with Varian UV detector 
mod-325. Elemental analyses (C, H, N) were performed and the results are within ±0.3% of the 
theoretical values, for compound 17a the results are within ±0.5% of the theoretical values. 
Compounds 2,
22
 2a,
22
 3,
27
 3a,
28
 5
29
 and 6,
30
 were synthesized as indicated in the literature. 
CAS1609 was a gift from Sanofi- Aventis Deutschland GmbH. 
General procedure for the preparation of 4, 4a and 5a 
A solution of Jones reagent 2.5 M (19 mL, 46.62 mmol) was added to a stirred solution of the 
appropriate alcohol (18.65 mmol) in acetone (150 mL), cooled at 0 °C. The mixture was allowed to 
reach rt and stirred for 4 h. iPrOH (10 mL) was added and the mixture was concentrated under 
reduced pressure. The residue was dissolved in EtOAc (150 mL) and extracted with a saturated 
solution of NaHCO3 (3 x 20 mL). The aqueous layers were acidified with 6 M HCl and extracted 
twice with EtOAc (50 mL). The combined organic layers were dried and concentrated under 
reduced pressure to give the desired compound. 
3-(3-Phenylfuroxan-4-yloxy)propanoic acid (4). 59% yield; white solid; mp = 136.5-137 °C 
(from toluene). 
1
H NMR (300 MHz, DMSO-d6, TMS):  = 3.01 (t, J = 6.0 Hz, 2H, –CH2COOH), 
4.78 (t, J = 6.0 Hz, 2H, –OCH2–), 7.41–7.50 (m, 3H, C6H5), 8.05– 8.07 (m, 2H, C6H5), 11.41 ppm 
(br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 33.3, 66.7, 107.3, 121.9, 125.7, 
128.8, 129.3, 161.9, 171.6 ppm; MS m/z 251 (M+H)
+
. 
3-(4-Phenylfurazan-3-yloxy)propanoic acid (4a). 71% yield; white solid; mp = 105.5–108 °C 
(from toluene). 
1
H NMR (300 MHz, DMSO-d6, TMS):  = 3.00 (t, J = 6.0 Hz, 2H, –CH2COOH), 
4.74 (t, J = 6.0 Hz, 2H, –OCH2–), 7.43–7.47 (m, 3H, C6H5), 7.92– 7.96 (m, 2H, C6H5), 11.41 ppm 
(br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 34.4, 68.0, 125.4, 127.9, 129.6, 
131.3, 145.6, 163.7, 177.0 ppm; MS m/z 235 (M+H)
+
. 
3-[(4-Phenylsulfonyl)furazan-3-yloxy]propanoic acid (5a). 68% yield; mp = 99.5–103.5 °C 
(from toluene). 
1
H NMR (300 MHz, DMSO-d6, TMS):  = 2.80 (t, J = 5.8 Hz, 2H, –CH2COOH), 
4.55 (t, J = 5.8 Hz, 2H, –OCH2–), 7.76 (t, 2H, C6H5), 7.92 (t, 1H, C6H5), 8.07 (d, 2H, C6H5), 12.62 
ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 33.3, 69.8, 128.5, 130.1, 136.1, 
136.7, 148.6, 160.7, 171.3 ppm; MS m/z 299 (M+H)
+
. 
Methyl 2-[(3-aminocarbonylfuroxan-4-yl)methyl]thioacetic acid (7). 
To a solution of 4-bromomethylfuroxan-3-carboxyamide (3.1 g, 14 mmol) in CH3CN (100 mL) 
methyl thioglycolate (1.3 mL, 14 mmol) and Et3N (1.95 mL, 14 mmol) were added. After 1 h the 
mixture was diluted with CH2Cl2 (100 mL), washed with H2O (100 mL), 1 M NaOH (50 mL), brine 
(50 mL), dried and concentrated under reduced pressure to give the title compound as a white solid, 
72% yield; mp = 92.5–93.5 °C (from iPr2O). 
1
H NMR (300 MHz, CDCl3, TMS):  = 3.33 (s, 2H, –
CH2COOCH3), 3.75 (s, 3H, -CH3) 4.16 (s, 2H, –CH2S–), 6.27 (br s, 1H, CONH2), 7.58 ppm (br s, 
1H, CONH2); 
13
C NMR (75 MHz, CDCl3, TMS):  = 26.7, 33.1, 52.7, 110.1, 156.1, 156.2, 170.3 
ppm; MS m/z 248 (M+H)
+
. 
Methyl 2-[(4-aminocarbonylfurazan-3-yl)methyl]thioacetic acid (7a) 
A solution of 7 (3.1 g, 12.54 mmol) in P(OMe)3 (20 mL) was heated under reflux for 17 h. The 
mixture was then poured into iced 6 M HCl (200 mL) and the white solid thus obtained was filtered. 
The crude product was purified by flash chromatography (PE/EtOAc 70:30 v/v) to give the title 
compound as a white solid, 90% yield; mp = 83–84 °C (from iPr2O). 
1
H NMR (300 MHz, CDCl3, 
TMS):  = 3.29 (s, 2H, –CH2COOCH3), 3.73 (s, 3H, CH3), 4.24 (s, 2H, –CH2S–), 6.29 (br s, 1H, 
CONH2), 6.83 ppm (br s, 1H, CONH2); 
13
C NMR (75 MHz, CDCl3, TMS):  = 23.8, 33.1, 52.6, 
146.9, 152.9, 158.7, 170.3 ppm; MS m/z 232 (M+H)
+
. 
General procedure for the preparation of 9 and 9a 
To a solution of the appropriate amide derivative (0.3 g, 1.21 mmol) in dry THF (10 mL) stirred 
under N2 at 0 °C, dry pyridine (200 L, 2.42 mmol) and, dropwise, (CF3CO)2O (320 L, 2.3 mmol) 
were added. After 20 min the reaction is complete; the mixture was diluted with Et2O (15 mL), 
washed with H2O (10 mL) and twice with 0.5 M HCl (10 mL). The organic layer was dried and 
concentrated under reduced pressure. The crude product was purified by flash chromatography 
(PE/EtOAc 90:10 v/v) to give the desired compound. 
Methyl 2-[(3-cyanofuroxan-4-yl)methyl]thioacetic acid (9). 89% yield; colorless oil. 
1
H NMR 
(300 MHz, CDCl3, TMS):  = 3.30 (s, 2H, –CH2COOCH3), 3.74 (s, 3H, CH3), 3.93 ppm (s, 2H, –
CH2S–); 
13
C NMR (75 MHz, CDCl3, TMS):  = 26.1, 32.9, 52.9, 96.6, 105.0, 154.4, 169.6 ppm; 
MS m/z 230 (M+H)
+
. 
Methyl 2-[(4-cyanofurazan-3-yl)methyl]thioacetic acid (9a). 84% yield; colorless oil. 
1
H NMR 
(300 MHz, CDCl3, TMS):  = 3.24 (s, 2H, –CH2COOCH3), 3.74 (s, 3H, CH3), 4.10 ppm (s, 2H, –
CH2S–); 
13
C NMR (75 MHz, CDCl3, TMS):  = 23.3, 32.8, 52.8, 106.9, 132.7, 153.9, 169.6 ppm; 
MS m/z 214 (M+H)
+
. 
General procedure for the preparation of 8, 8a, 10 and 10a 
To a solution of the appropriate methyl ester (6.3 mmol) in dioxane (30 mL), 6 M HCl (30 mL) was 
added and the mixture heated at 70 °C for 4 h. After concentration under reduced pressure, the 
residue was dissolved in EtOAc (30 mL) and the solution washed with H2O (50 mL), and extracted 
twice with a saturated solution of NaHCO3 (30 mL). The aqueous layers were acidified and 
extracted twice with EtOAc (30 mL). The organic layers were washed with brine (50 mL), dried 
and concentrated under reduced pressure to give the desired product. 
2-[(3-Aminocarbonylfuroxan-4-yl)methyl]thioacetic acid (8). 83% yield; white solid; mp = 110–
112 °C (from toluene). 
1
H NMR (300 MHz, DMSO-d6, TMS):  = 3.36 (s, 2H, –CH2COOH), 4.05 
(s, 2H, –CH2S–), 7.79 (br s, 1H, CONH2), 8.45 (br s, 1H, CONH2), 12.69 ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 26.3, 33.3, 110.3, 155.8, 156.6, 171.0 ppm; MS m/z 234 
(M+H)
+
. 
2-[(4-Aminocarbonylfurazan-3-yl)methyl]thioacetic acid (8a). 67% yield; white solid; mp = 
151–157 °C (toluene). 1H NMR (300 MHz, DMSO-d6, TMS):  = 3.29 (s, 2H, –CH2COOH), 4.14 
(s, 2H, –CH2S–), 8.18 (br s, 1H, CONH2), 8.54 (br s, 1H, CONH2), 12.75 ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 23.3, 33.4, 148.3, 153.8, 158.4, 170.9 ppm; MS m/z 218 
(M+H)
+
. 
2-[(3-Cyanofuroxan-4-yl)methyl]thioacetic acid (10). 97% yield; white solid; mp = 87–88 °C 
(from toluene). 
1
H NMR (300 MHz, DMSO-d6, TMS):  = 3.35 (s, 2H, –CH2COOH), 4.05 (s, 2H, –
CH2S–), 12.64 ppm (br s, 1H, COOH); 
13
C NMR (75MHz, DMSO-d6, TMS): d = 25.9, 33.3, 97.8, 
105.7, 155.4, 170.7 ppm; MS m/z 216 (M+H)
+
. 
2-[(4-Cyanofurazan-3-yl)methyl]thioacetic acid (10a). 92% yield; white solid; mp = 34–37 °C 
(from toluene). 
1
H NMR (300 MHz, CDCl3, TMS):  = 3.32 (s, 2H, –CH2COOH), 4.16 (s, 2H, –
CH2S–), 10.87 ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, CDCl3, TMS):  = 23.6, 33.1, 107.2, 
133.0, 154.1, 175.7 ppm; MS m/z 200 (M+H)
+
. 
General procedure for the preparation of 13, 13a, 14 and 14a. 
SOCl2 (334 L, 4.58 mmol) and a few drops of dry DMF were added to a solution of the 
appropriate carboxylic acid (3.82 mmol) in dry THF (20 mL), stirred under N2 at rt. Stirring was 
continued for 7 h at rt. The solution of the acyl chloride thus obtained was slowly added to a stirred 
solution of salicylic acid (0.53 g, 3.82 mmol) and dry Py (463 L, 5.73 mmol) in dry THF (20 mL) 
kept under N2 at 0 °C. The mixture was allowed to reach rt and then stirred overnight. The mixture 
was diluted with Et2O (50 mL) and washed twice with 2 M HCl (50 mL). The combined organic 
layers were dried and concentrated under reduced pressure. The crude product was purified by 
preparative HPLC (Lichrospher 250–25 C18, CH3CN/H2O/TFA 50:50:0.1, flow 39 mL/min, 224 
nm, injection 4 mL, solution 51 mg/mL) to give the desired compound. 
2-({3-[(3-Phenylfuroxan-4-yl)oxy]propanoyl}oxy)benzoic acid (13). 61% yield; white solid; mp 
= 152–154 °C (from toluene). 1H NMR (300 MHz, DMSO-d6, TMS):  = 3.27 (t, J = 6.0 Hz, 2H, –
CH2COO–), 4.80 (t, J = 6.0 Hz, 2H, –CH2O–), 7.14–8.07 (m, 9H, C6H4+ C6H5), 13.16 ppm (br s, 
1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 33.9, 66.5, 107.9, 122.3, 124.1, 124.2, 
126.6, 126.7, 129.3, 131.1, 131.9, 134.3, 150.3, 162.4, 165.8, 169.4 ppm; MS m/z 371 (M+H)
+
. 
Anal. Calcd for C18H14N2O7: C, 58.38; H, 3.81; N, 7.56. Found: C, 58.55; H, 3.91; N, 7.34. 
2-({3-[(4-Phenylfurazan-3-yl)oxy]propanoyl}oxy)benzoic acid (13a). 37% yield; white solid; mp 
= 141–146 °C (from toluene). 1H NMR (300 MHz, DMSO-d6, TMS):  = 3.25 (t, J = 6.0 Hz, 2H, –
CH2COO–), 4.78 (t, J = 6.0 Hz, 2H, –CH2O–), 7.18–7.98 (m, 9H, C6H4 + C6H5), 13.16 ppm (br s, 
1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 33.8, 68.2, 123.9, 124.0, 124.4, 126.5, 
127.4, 129.4, 131.3, 131.7, 134.1, 145.4, 150.1, 163.3, 165.6, 169.2 ppm; MS m/z 355 (M+H)
+
. 
Anal. Calcd for C18H14N2O6: C, 61.02; H, 3.98; N, 7.91. Found: C, 61.13; H, 4.02; N, 7.74. 
2-[(3-{[(3-Phenylsulfonyl)furoxan-4-yl]oxy}propanoyl)oxy]benzoic acid (14). 32% yield; white 
solid; mp = 169.5–170 °C (from toluene). 1H NMR (300 MHz, DMSO-d6, TMS):  = 3.16 (t, J = 
6.0 Hz, 2H, –CH2COO–), 4.71 (t, J = 6.0 Hz, 2H, –CH2O–), 7.21 (d, 1H, C6H4), 7.43 (t, 1H, C6H4), 
7.63–7.70 (m, 3H, C6H4 + C6H5), 7.86 (t, 1H, C6H4), 7.98 (d, 1H, C6H4), 8.08 (d, 2H, C6H5), 13.16 
ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 33.3, 66.6, 110.4, 123.6, 123.7, 
126.3, 128.2, 129.8, 131.5, 133.9, 136.0, 137.1, 149.8, 158.6, 165.4, 168.6 ppm; MS m/z 435 
(M+H)
+
. Anal. Calcd for C18H14N2O9S: C, 49.77; H, 3.25; N, 6.45. Found: C, 49.67; H, 3.28; N, 
6.53. 
2-[(3-{[(4-Phenylsulfonyl)furazan-3-yl]oxy}propanoyl)oxy]benzoic acid (14a). 38% yield; white 
solid; mp = 139.5–140 °C (from toluene). 1H NMR (300 MHz, DMSO-d6, TMS):  = 3.16 (t, J = 
5.8 Hz, 2H, –CH2COO–), 4.71 (t, J = 5.8 Hz, 2H, –CH2O–), 7.21 (d, 1H, C6H4), 7.43 (t, 1H, C6H4), 
7.63–7.70 (m, 3H, C6H4 + C6H5), 7.86 (t, 1H, C6H5), 7.98 (d, 1H, C6H4), 8.08 (d, 2H, C6H5),13.16 
ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):  = 33.4, 69.0, 123.6, 123.7, 126.3, 
128.6, 130.0, 131.4, 133.9, 136.0, 136.6, 148.6, 149.8, 160.7, 165.3, 168.6 ppm; MS m/z 419 
(M+H)
+
. Anal. Calcd for C18H14N2O8S 0.25 H2O: C, 51.12; H, 3.46; N, 6.62. Found: C, 51.00; H, 
3.30; N, 6.54. 
General procedure for 17, 17a, 18 and 18a 
SOCl2 (190 L, 2.57 mmol) and dry DMF (1 mL) were added to a solution of the appropriate 
carboxylic acid (2.15 mmol) in dry CH2Cl2 (10 mL), stirred under N2 at rt. Stirring was continued 
for 1 h at rt. The solution of the acyl chloride thus obtained was slowly added to a stirred solution of 
salicylic acid (0.24 g, 1.72 mmol) and dry Py (260 L, 3.22 mmol) in dry CH2Cl2 (20 mL) kept 
under N2 at 0 °C. The mixture was allowed to reach rt and then stirred overnight. The mixture was 
washed twice with 2 M HCl (20 mL). The combined organic layers were dried and concentrated 
under reduced pressure. The crude product was purified as follows. 
2-{[(3-Aminocarbonylfuroxan-4-yl)methyl]thioacetoxy}benzoic acid (17). Purified by flash 
chromatography (eluent PE/EtOAc/HCOOH 70:30:0.1 v/v/v) to give the title compound in 69% 
yield as white solid; mp = 143.5–144.5 °C (from toluene). 1H NMR (300 MHz, DMSO-d6, TMS):  
= 3.74 (s, 2H, –CH2COO–), 4.15 (s, 2H, –CH2S–), 7.21 (d, 1H, C6H4), 7.41 (t, 1H, C6H4), 7.67 (t, 
1H, C6H4), 7.82 (br s, 1H, CONH2), 7.95 (d, 1H, C6H4), 8.48 ppm (br s, 1H, CONH2); 
13
C NMR (75 
MHz, DMSO-d6, TMS):   = 26.2, 33.1, 110.0, 119.1, 123.4, 126.3, 131.4, 133.9, 149.8, 155.6, 
156.3, 165.4, 168.4 ppm; MS m/z 354 (M+H)
+
. Anal. Calcd for C13H11N3O7S: C, 44.19; H, 3.14; N, 
11.89. Found: C, 43.80; H, 3.18; N, 12.00. 
2-{[(4-Aminocarbonylfurazan-3-yl)methyl]thioacetoxy}benzoic acid (17a). Purified by flash 
chromatography (eluent CH2Cl2/MeOH/HCOOH 98:2:0.1 v/v/v) to give the title compound in 69% 
yield as white solid; mp = 154–157 °C (from toluene). 1H NMR (300 MHz, DMSO-d6, TMS):  = 
3.70 (s, 2H, –CH2COO–), 4.25 (s, 2H, –CH2S–), 7.21 (d, 1H, C6H4), 7.39 (t, 1H, C6H4), 7.68 (t, 1H, 
C6H4), 7.95 (d, 1H, C6H4), 8.20 (br s, 1H, CONH2), 8.57 (br s, 1H, CONH2), 13.20 ppm (br s, 1H, 
COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):   = 23.4, 33.3, 123.7, 126.3, 131.4, 133.9, 148.1, 
149.8, 153.2, 158.2, 165.4, 168.3, 170.7 ppm; MS m/z 338 (M+H)
+
. Anal. Calcd for C13H11N3O6S 
0.5 H2O: C, 45.09; H, 3.49; N, 12.13. Found: C, 45.27; H, 3.36; N, 11.65. 
2-{[(3-Cyanofuroxan-4-yl)methyl]thioacetoxy}benzoic acid (18). Purified by reverse phase flash 
chromatography (eluent H2O/CH3CN/TFA 60:40:0.1 v/v/v) to give the title compound in 38% yield 
as white solid; mp = 121.5–124.5 °C (from toluene). 1H NMR (300 MHz, DMSO-d6, TMS):   = 
3.82 (s, 2H, –CH2COO–), 4.20 (s, 2H, –CH2S–), 7.19 (d, 1H, C6H4), 7.42 (t, 1H, C6H4), 7.67 (t, 1H, 
C6H4), 7.96 (d, 1H, C6H4), 13.18 ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):   
= 25.4, 32.8, 98.7, 106.2, 123.4, 123.7, 126.4, 131.4, 133.9, 149.8, 155.8, 165.3, 168.2 ppm; MS 
m/z 336 (M+H)
+
. Anal. Calc. for C13H9N3O6S: C, 46.57; H, 2.70; N, 12.53. Found: C, 46.27; H, 
2.76; N, 12.27. 
2-{[(4-Cyanofuroxan-3-yl)methyl]thioacetoxy}benzoic acid (18a). Purified by preparative HPLC 
(Lichrospher 250–25 C18, CH3CN/H2O/TFA 45:55:0.1, flow 39 mL/min,  224 nm, injection 3 
mL, solution 51 mg/mL) to give the title compound in 46% yield as a white solid; mp = 114–115.5 
°C (from toluene). 
1
H NMR (300 MHz, DMSO-d6, TMS):  = 3.76 (s, 2H, –CH2COO–), 4.35 (s, 
2H, –CH2S–), 7.16 (d, 1H, C6H4), 7.41 (t, 1H, C6H4), 7.68 (t, 1H, C6H4), 7.95 (d, 1H, C6H4), 13.19 
ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, DMSO-d6, TMS):   = 23.1, 33.3, 107.7, 123.3, 123.6, 
126.4, 131.4, 133.7, 133.9, 149.8, 155.1, 165.3, 168.3 ppm; MS m/z 320 (M+H)
+
. Anal. Calcd for 
C13H9N3O5S 1.5 H2O: C, 45.09; H, 3.49; N, 12.13. Found: C, 45.18; H, 3.17; N, 12.47. 
Stability studies 
Evaluation of stability in aqueous buffered solutions 
A solution of each compound (10 mM) in acetonitrile was added to HCl 0.1 M or to phosphate 
buffer pH 7.4 (50 mM) preheated at 37 °C; the final concentration of the compound was 100 M. 
The resulting solution was maintained at 37 ± 0.5 °C and, at appropriate time intervals, a 20 L 
aliquot of reaction solution was analyzed by RP-HPLC, as described below. 
Stability in human serum 
A solution of each compound (10 mM) in acetonitrile was added to human serum (Sigma) 
preheated to 37 °C; the final concentration of the compound was 200 M. The resulting solution 
was incubated at 37 ± 0.5 °C and, at appropriate time intervals, 300 L of reaction mixture were 
withdrawn and added to 300 L of acetonitrile containing 0.1% trifluoroacetic acid, in order to 
deproteinize the serum. The sample was sonicated, vortexed and then centrifuged for 10 min at 
2150 g, the clear supernatant was filtered through 0.45 m PTFE filters (Alltech) and analyzed by 
RP-HPLC The reverse-phase HPLC procedure separated and quantitated the remaining compound 
and salicylic acid. HPLC analyses were performed with a HP 1100 chromatograph system (Agilent 
Technologies, Palo Alto, CA, USA) equipped with a quaternary pump (model G1311A), a 
membrane degasser (G1379A), and a diode-array detector (DAD) (model G1315B) integrated in the 
HP1100 system. Data analysis was done by the HP ChemStation system (Agilent Technologies). 
The analytical column was a Nucleosil 100-5C18 Nautilus (250 x 4.6 mm, 5 m particle size) 
(Macherey-Nagel). The mobile phase consisting of acetonitrile/water (55:45) with 0.1% 
trifluoroacetic acid and the flow-rate was 1.2 mL/min. The injection volume was 20 L (Rheodyne, 
Cotati, CA). The column effluent was monitored at 226 nm (for compounds) and 240 nm (for 
salicylic acid) referenced against a 600 nm wavelength. Quantitation was done using calibration 
curves of compounds and relative metabolites chromatographed under the same conditions; the 
linearity of the calibration curves was determined in a concentration range of 1–200 M (r2 >0.99). 
Anti-inflammatory activity 
Male Wistar rats, weighing 180–200 g (Harlan, S. Pietro al Natisone, Italy) were individually 
housed in hanging stainless-steel cages with grid floors, at constant room temperature (25 ± 1 °C) 
and humidity (60 ± 5%), with an artificial 12:12 h light/dark cycle. Edema was induced in 
conscious rats by intraplantar injection into the right hindpaw of 0.1 mL of 1% carrageenan, 
suspended in 1% carboxymethylcellulose (CMC). Immediately after carrageenan injection, 
compounds or vehicle (CMC, 1%) were administered intragastrically to different groups of rats in a 
volume of 10 mL kg
-1
. Salicylic acid and NO-aspirin derivatives were administered at a dose 
equimolar with aspirin 120 mg kg
-1
. Groups of 6–8 animals were used. Paw volume was measured 
with a water plethysmometer (Basile, Comerio, Italy) immediately before carrageenan injection and 
3 h afterwards. The edema reduction in treated animals was expressed as percentage inhibition of 
the edema observed in vehicle-treated animals, considered as 100. The results obtained are 
presented as mean ± SEM. Statistical analysis was performed with ANOVA followed by Dunnett 
test. 
Gastrotoxicity 
Male Wistar rats, weighing 180–200 g (Harlan, S. Pietro al Natisone, Italy) were individually 
housed in hanging stainless-steel cages with grid floors, at constant room temperature (25 ± 1 °C) 
and humidity (60 ± 5%), with an artificial 12:12 h light/dark cycle. They were deprived of food but 
not of water 24 h before the experiments. Groups of rats (n = 8–10) were given aspirin 120 mg kg-1 
by intragastric route or equimolar doses of the compounds under study (vehicle CMC 1%). Rats 
were sacrificed 3 h after the administration of the compounds. Immediately after the sacrifice, the 
stomachs were removed, opened along the lesser curvature and examined for the assessment of 
mucosal lesions. The stomachs were laid on a flat surface under a stereomicroscope. The glandular 
mucosa was examined and each individual hemorrhagic lesion was measured along its greatest 
length (<1 mm: rating = 1; 1–2 mm: rating = 2; >2 mm: rating according to their greatest length). 
The lengths of the lesions were summed to give an overall total, designated as the lesion index, for 
each stomach. The results obtained are presented as mean ± SEM. Statistical analysis was 
performed with ANOVA followed by Newman–Keuls test. 
Inhibition of human platelet aggregation in vitro 
Venous blood samples were obtained from healthy volunteers who had not taken any drug for at 
least two weeks. Volunteers, who were treated according to Helsinki protocol for biomedical 
experimentation, gave their informed consent to the use of blood samples for research purposes. 
Platelet rich plasma (PRP) was prepared by centrifugation of citrated blood at 200g for 20 min. 
Aliquots (500 L) of PRP were added into aggregometer (Chrono-log4902D) cuvettes and 
aggregation was recorded as increased light transmission under continuous stirring (1000 rpm) at 37 
°C for 10 minutes after addition of the stimulus. Collagen at submaximal concentration (0.8–1.5 
lgmL
-1
) was used as platelet activator in PRP. Compounds under study were preincubated with PRP 
10 min before addition of the stimulus (collagen). Vehicle alone (0.5% DMSO) added to PRP did 
not affect platelet function in control samples. The role of NO and sGC in the inhibitory effect was 
investigated using the sGC inhibitor, ODQ (50 M). At least five experiments for each compound 
were performed. To study the antagonism at the thromboxane receptor human blood was 
anticoagulated with citrate solution and treated with 1 mM acetylsalicylic acid; PRP was prepared 
as described above. PRP samples were incubated with compounds or vehicle (0.5% DMSO) and 
challenged with the agonist U-46619 (0.5–2.5 M). Incubation and registration times were the same 
as described previously. At least four experiments for each compound were performed. The 
antiaggregatory activity of tested compounds is evaluated as% inhibition of platelet aggregation 
compared to control samples. For most active compounds IC50 values could be calculated by 
nonlinear regression analysis, otherwise% inhibition at maximal concentration tested (300 M) is 
reported. 
Vasodilator activity 
Thoracic aortas were isolated from male Wistar rats weighing 180–200 g. As few animals as 
possible were used. The purposes and the protocols of our studies have been approved by Ministero 
della Salute, Rome, Italy. The endothelium was removed and the vessels were helically cut: three 
strips were obtained from each aorta. The tissues were mounted under 1.0 g tension in organ baths 
containing 30 mL of Krebs-bicarbonate buffer with the following composition (mM): NaCl 111.2, 
KCl 5.0, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.0, NaHCO3 12.0, glucose 11.1, maintained at 37 °C and 
gassed with 95% O2-5% CO2 (pH = 7.4). The aortic strips were allowed to equilibrate for 120 min 
and then contracted with 1 M L-phenylephrine. When the response to the agonist reached a 
plateau, cumulative concentrations of the vasodilating agent were added. Results are expressed as 
EC50 ± SE (lM). The effects of 1 M ODQ on relaxation were evaluated in separate series of 
experiments in which it was added to the organ bath 5 min before the contraction. Responses were 
recorded by an isometric transducer connected to the MacLab System PowerLab. Addition of the 
drug vehicle (DMSO) had no appreciable effect on contraction level. 
COX-1 inhibition 
In order to evaluate COX-1 inhibitory activity, washed platelets from individual donors were 
prepared as described elsewhere.
18
 Aliquots of platelets (200 L at 108 cells mL-1) were incubated 
with inhibitors at different concentrations (diluted from 400-fold concentrated solutions in DMSO) 
for 30 min at 37 °C, before addition of calcium ionophore (A23187, 2 M). After 10 min at 37 °C, 
the reactions were terminated with 100 L of methanol. TXB2 in the supernatant was determined by 
enzyme immunoassay (Cayman Chemical). Percent inhibition of TXB2 production in compound-
treated samples was calculated by comparison with untreated control samples. Background (no 
ionophore) TXB2 production was subtracted from each value obtained in the presence of ionophore. 
COX-2 inhibition 
In order to evaluate COX-2 inhibitory activity, human monocytes were isolated from buffy coats 
obtained from the SIMT (Banca del sangue, AOU San Giovanni Battista Hospital, Turin, Italy). 
Mononuclear cells were isolated as described elsewhere.18 The monocytes (106 cells mL-1 were 
incubated with LPS (10 g mL-1) for 18 h at 37 °C in a 5% CO2 atmosphere. Aliquots of LPS-
stimulated monocytes were centrifuged (300g, 8 min) and resuspended in fresh FCS-free RPMI-
1640 medium. Each compound (diluted from 200-fold concentrated solutions in DMSO) was added 
at different concentrations to the monocyte suspensions; the aliquots of monocytes were then 
incubated at 37 °C in a 5% CO2 atmosphere for 30 min, prior to stimulation with arachidonic acid 
(100 M) for 15 min. Cell suspensions were centrifuged and cell-free supernatants were stored at -
20 °C until eicosanoid determination was completed. PGE2 in the supernatant was determined by 
EIA (Cayman Chemical). Percent inhibition of PGE2 production in compound-treated samples was 
calculated versus untreated control samples. Background (no arachidonic acid) PGE2 production was 
subtracted from each value obtained in the presence of arachidonic acid. 
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Figure 1. (A) Structure of aspirin and general structures of NO-donor aspirin codrugs; (B) general 
structure of NO-donor salicylic acid co-drugs. 
 
Figure 2. Structure of the new compounds. 
 
 
Scheme 1. Reagents and conditions: (i) Jones reagent, acetone, 0 °C; (ii) HSCH2COOCH3, Et3N, 
CH3CN; (iii) (CF3CO)2O, Py, THF, 0 °C; (iv) 6 M HCl, dioxane, 70 °C; (v) P(OCH3)3, reflux. 
 
Scheme 2. Reagents and conditions: (i) SOCl2, dry THF; (ii) Py, salicylic acid, dry THF; (iii) 
SOCl2, dry CH2Cl2; (iv) Py, salicylic acid, dry CH2Cl2. 
 
 
Table 1. Stability in aqueous buffered solutions and human serum of aspirin (1) and of 
compounds 13, 13a, 14, 14a, 17, 17a, 18 and 18a incubated at 37 °C. 
 
Table 2. Antiaggregatory, vasodilator, anti-inflammatory and ulcerogenic activity of ASA, salicylic 
acid and compounds 13, 13a, 14, 14a, 17, 17a, 18 and 18a. 
 
 
